Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Photobiomodulation
5 evidence topics · 3 sources
FDA De Novo authorization: indications for use
Treatment regimen
LIGHTSITE III: best-corrected visual acuity in the FDA review
LIGHTSITE III: new-onset and existing geographic atrophy at Month 13
“A very small number of eyes presented with noncenter involving GA at baseline (PBM, n = 6; Sham, n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using FAF analysis, a numerical trend showed an increase in GA lesion area in Sham (1.48, SE 0.94; SD 1.62) compared with PBM-treated eyes (1.16, SE 0.66; SD 1.32, P = 0.75) at Month 13 (change from baseline; Table 2; Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The occurrence of new GA was significantly higher in the Sham versus PBM group (P = 0.024, Fisher exact test, odds ratio 9.4) (Table 2; Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote